Comparison
7p22 1 Microduplication Syndrome C4707093 vs 6 Phosphogluconolactonase Deficiency C1868355
Clinical comparison between 7p22 1 Microduplication Syndrome and 6 Phosphogluconolactonase Deficiency for differential diagnosis and treatment planning.
7p22 1 Microduplication Syndrome C4707093
A rare genetic variation involving duplication of genetic material at chromosome 7. This can affect development and cause developmental delays, distinctive features, and other health concerns. Management focuses on supportive care and therapies.
6 Phosphogluconolactonase Deficiency C1868355
A rare metabolic disorder caused by deficiency of an enzyme involved in sugar processing. This can lead to accumulation of certain metabolites. Treatment involves dietary management and supportive measures tailored to the individual.
6 comparison axes
Onset
7p22 1 Microduplication Syndrome C4707093
Variable
6 Phosphogluconolactonase Deficiency C1868355
Variable
Onset patterns differ
Severity
7p22 1 Microduplication Syndrome C4707093
moderate
6 Phosphogluconolactonase Deficiency C1868355
moderate
Different severity levels
Chronic
7p22 1 Microduplication Syndrome C4707093
Chronic
6 Phosphogluconolactonase Deficiency C1868355
Chronic
Differing course
Communicable
7p22 1 Microduplication Syndrome C4707093
No
6 Phosphogluconolactonase Deficiency C1868355
No
Different transmission
Body System
7p22 1 Microduplication Syndrome C4707093
congenital
6 Phosphogluconolactonase Deficiency C1868355
metabolic
Same/different system
Category
7p22 1 Microduplication Syndrome C4707093
genetic
6 Phosphogluconolactonase Deficiency C1868355
metabolic
Different category
Bottom line
7p22-1-microduplication-syndrome-C4707093 and 6-phosphogluconolactonase-deficiency-C1868355 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 7p22 1 Microduplication Syndrome C4707093 | 6 Phosphogluconolactonase Deficiency C1868355 | Discriminating power |
|---|---|---|---|
| Developmental concerns | Delays and distinctive features are described, but not universal. | Neurodevelopment is not established as a defining feature. | Moderate |
| Metabolic symptoms | No specific metabolite accumulation is established. | Enzyme deficiency may allow metabolite accumulation; symptoms vary. | Moderate |
| Congenital pattern | A congenital chromosomal change may affect multiple systems. | Primarily a metabolic enzyme disorder rather than a chromosomal syndrome. | High |
When to favor each condition
Choose 7p22 1 Microduplication Syndrome C4707093 when
Chromosomal microarray suggests 7p22.1 duplication
Genetic result directly supports the chromosomal condition.
High
Developmental delay with possible dysmorphic features
Fits reported concerns, but confirmation requires genetics.
Moderate
Family chromosomal rearrangement evaluation
Inheritance and recurrence counseling depend on parental studies.
Moderate
Choose 6 Phosphogluconolactonase Deficiency C1868355 when
Enzyme or genetic testing indicates PGLS deficiency
A specific metabolic diagnosis requires laboratory confirmation.
High
Unexplained metabolite abnormality in sugar metabolism
May prompt targeted metabolic evaluation; result alone is not diagnostic.
Moderate
Dietary triggers suspected by clinician
Management is individualized; no universal diet is established here.
Low
How key tests differ
| Test | 7p22 1 Microduplication Syndrome C4707093 | 6 Phosphogluconolactonase Deficiency C1868355 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May detect duplication at 7p22.1. | Not expected to identify this enzyme deficiency. | A positive array supports the left condition; clinical correlation remains necessary. |
| PGLS enzyme or gene testing | No characteristic PGLS abnormality is established. | May confirm enzyme deficiency or related variant. | Interpret only with metabolic and genetic expertise. |
| Metabolic studies | No specific diagnostic metabolite pattern is established. | May show pathway-related abnormalities, but cutoffs are not defined here. | Abnormal results are findings, not automatically a diagnosis. |
Prognosis comparison
7p22 1 Microduplication Syndrome C4707093
- Outcome
- Chronic course with variable developmental impact; exact outcomes are not established.
- Factors
- Duplication extent, associated findings, therapies, and comorbidities may influence needs.
6 Phosphogluconolactonase Deficiency C1868355
- Outcome
- Chronic metabolic condition with variable expression; prognosis is not established.
- Factors
- Enzyme function, metabolic control, illness, and individualized nutrition may matter.
Time frame: Lifelong follow-up is generally relevant, but milestones cannot be specified.
Neither condition is communicable; etiology and monitoring needs differ.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental disability | Possible but variable; severity is not predictable from the label alone. Not established as characteristic from the supplied data. Use individualized developmental assessment. |
| Metabolic decompensation | Not an established feature. Possible concern in an enzyme disorder, but risk is not quantified here. Seek urgent care for concerning illness; no threshold is established. |
| Multisystem health needs | Supportive therapies may address developmental and medical concerns. Needs may center on nutrition and metabolic monitoring. Complication profiles are incompletely defined. |
Patient education highlights
- HighDifferent causes
One is a chromosomal duplication; the other is a rare enzyme deficiency. Testing distinguishes them.
- HighNo fixed prognosis
Available descriptions are limited. Outcomes and severity vary and should be discussed individually.
- MediumCare plan
Supportive therapies, genetics, and metabolic follow-up are tailored; do not start restrictive diets without clinician advice.